101 related articles for article (PubMed ID: 22260151)
1. Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.
Fehm T; Zwirner M; Wallwiener D; Seeger H; Neubauer H
BMC Cancer; 2012 Jul; 12():308. PubMed ID: 22824103
[TBL] [Abstract][Full Text] [Related]
2. p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.
Kuroda J; Kimura S; Segawa H; Sato K; Matsumoto S; Nogawa M; Yuasa T; Kobayashi Y; Yoshikawa T; Ottmann OG; Maekawa T
Cancer Sci; 2004 Feb; 95(2):186-92. PubMed ID: 14965371
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment.
Boran G; Tavakoli S; Dierking I; Kamali AR; Ege D
Sci Rep; 2020 May; 10(1):7827. PubMed ID: 32385391
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.
Misso G; Porru M; Stoppacciaro A; Castellano M; De Cicco F; Leonetti C; Santini D; Caraglia M
Cancer Biol Ther; 2012 Dec; 13(14):1491-500. PubMed ID: 22990205
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation.
Hahm ER; Kim SH; Pore SK; Mathan SV; Singh RP; Singh SV
Mol Carcinog; 2024 Feb; 63(2):301-313. PubMed ID: 37921547
[TBL] [Abstract][Full Text] [Related]
6. Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer.
Akoury E; Ahangar P; Nour A; Lapointe J; Guérard KP; Haglund L; Rosenzweig DH; Weber MH
Cancer Cell Int; 2019; 19():28. PubMed ID: 30787671
[TBL] [Abstract][Full Text] [Related]
7. Minimally effective concentration of zoledronic acid to suppress osteoclasts
Li P; Zhao Z; Wang L; Jin X; Shen Y; Nan C; Liu H
Exp Ther Med; 2018 Jun; 15(6):5330-5336. PubMed ID: 29904413
[TBL] [Abstract][Full Text] [Related]
8. [Experimental study on inhibitory effect of zoledronic acid on the action style of the osteoclast].
Li P; Yang H; Jia N; Jin X; Xu D; Shen Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2017 Feb; 34(1):78-82. PubMed ID: 29717592
[TBL] [Abstract][Full Text] [Related]
9. Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.
Hoeres T; Wilhelm M; Smetak M; Holzmann E; Schulze-Tanzil G; Birkmann J
Clin Exp Immunol; 2018 Apr; 192(1):54-67. PubMed ID: 29235095
[TBL] [Abstract][Full Text] [Related]
10. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
Fanale D; Amodeo V; Bazan V; Insalaco L; Incorvaia L; Barraco N; Castiglia M; Rizzo S; Santini D; Giordano A; Castorina S; Russo A
Oncotarget; 2016 May; 7(20):29321-32. PubMed ID: 27081088
[TBL] [Abstract][Full Text] [Related]
11. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
[TBL] [Abstract][Full Text] [Related]
12. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
13. The best of both worlds - managing the cancer, saving the bone.
Makhoul I; Montgomery CO; Gaddy D; Suva LJ
Nat Rev Endocrinol; 2016 Jan; 12(1):29-42. PubMed ID: 26503674
[TBL] [Abstract][Full Text] [Related]
14. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
15. The effects of zoledronate on monocyte-derived dendritic cells from melanoma patients differ depending on the clinical stage of the disease.
Failli A; Legitimo A; Orsini G; Romanini A; Consolini R
Hum Vaccin Immunother; 2014; 10(11):3375-82. PubMed ID: 25483657
[TBL] [Abstract][Full Text] [Related]
16. An effective therapy to painful bone metastases: cryoablation combined with zoledronic acid.
Li F; Wang W; Li L; Chang Y; Su D; Guo G; He X; Li M
Pathol Oncol Res; 2014 Oct; 20(4):885-91. PubMed ID: 24781761
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the attenuation of breast cancer bone metastasis in mice by zoledronic acid using (99m)Tc bone scintigraphy.
Wu C; Yang S; Sun Z; Han X; Ye Y; Liu S
Pathol Oncol Res; 2014 Jul; 20(3):747-54. PubMed ID: 24610002
[TBL] [Abstract][Full Text] [Related]
18. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
Fasching PA; Jud SM; Hauschild M; Kümmel S; Schütte M; Warm M; Hanf V; Grab D; Krocker J; Stickeler E; Kreienberg R; Müller T; Kühn T; Wolf C; Kahlert S; Paepke S; Berghorn M; Muth M; Baier M; Wackwitz B; Schulz-Wendtland R; Beckmann MW; Lux MP
BMC Cancer; 2014 Feb; 14():66. PubMed ID: 24499441
[TBL] [Abstract][Full Text] [Related]
19. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.
Insalaco L; Di Gaudio F; Terrasi M; Amodeo V; Caruso S; Corsini LR; Fanale D; Margarese N; Santini D; Bazan V; Russo A
J Cell Mol Med; 2012 Sep; 16(9):2186-95. PubMed ID: 22260151
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
